Introduction {#sec1-1}
============

Coronary artery disease (CAD) is one of the most fatal cardiovascular diseases with a high hospitalization rate and mortality ([@ref1]). Inflammation has been identified to participate in CAD partly by acting on atherosclerosis ([@ref2]). Based on the critical role of various inflammatory factors and mediators in the pathophysiological processes of atherosclerosis, there are increasing numbers of investigations focused on novel and efficient therapies to ameliorate the immune and inflammatory response of atherosclerosis ([@ref3]-[@ref6]).

The interleukin (IL) 17 cytokine family, including IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25), and IL-17F, was found to be involved in inflammatory responses ([@ref7], [@ref8]). Growing evidence showed that the IL-17 cytokine family played important roles in cardiovascular diseases. For instance, IL-17A was increased in the plasma of unstable angina and acute myocardial infarction patients, and no significance was noted between patients with complex and simple lesions ([@ref9], [@ref10]). Animal studies also showed that IL-17A is increased in the left ventricle infarcted region of rats after myocardial infarction. Moreover, endothelial cells in the infarcted region were observed to stain positively for IL-17A, which suggested that IL-17A might be involved in cardiac repair and inflammation ([@ref11]). Liao et al. ([@ref12]) reported that IL-17A might have the capacity to regulate cardiomyocyte apoptosis and neutrophil infiltration to participate in myocardial ischemia/reperfusion injury ([@ref13]).

IL-25 is also a member of the IL-17 cytokine family, which possesses unique structures and has the capacity to regulate immune and inflammatory responses ([@ref14]) and angiogenesis ([@ref15]). Further evidence showed that IL-25 promotes cell proliferation, inhibits apoptosis ([@ref16]), and affects the development of fibrosis and hypoxic ischemic injury ([@ref17]), tumor metastasis ([@ref18]) and metabolism processes ([@ref19], [@ref20]). Experiments using IL-25 for the treatment of atherosclerosis-prone apolipoprotein (apo) E-deficient mice showed its ability to protect against atherosclerosis without affecting the adaptive Th2 responses ([@ref21]). However, the IL-25 levels in patients with CAD are still unclear. In this study, we detected the serum and coronary artery tissue expression of IL-25 in CAD and attempted to explore the possible clinical associations between IL-25 and CAD.

Methods {#sec1-2}
=======

Collection of coronary artery tissues {#sec2-2}
-------------------------------------

This study protocol was approved by the Medical Ethics Committee of the Renmin Hospital of Wuhan University. All donors or their families signed an informed consent form before tissue harvesting. Human coronary artery tissue with atherosclerotic plaques (n=10) was obtained from CAD patients undergoing heart transplantation, whereas control arteries (n=6) were obtained from normal donors who failed to match for a transplant recipient. All donors in whom other diseases were reported to affect the expression of IL-25 including allergic diseases, autoimmune diseases, and tumor were ruled out. The tissues were fixed in formalin at the end of the surgery and then embedded in paraffin for immunofluorescence.

Immunofluorescence {#sec2-3}
------------------

After the tissue samples were fixed in formalin, coronary artery tissues embedded in paraffin were cut into 5 µm slices. After washing in PBS, the sections were subsequently sealed with 8% sheep serum for 1 h and incubated at 4°C overnight with primary antibodies. Immunofluorescent staining was used for IL-25 expression by anti-IL-25 antibodies (R&D Systems, USA). Double immunofluorescent staining was used to detect the source of IL-25 by anti-CD4 antibodies (Biolegend, USA), anti-CD68 antibodies (Abcam, UK), and anti-α- smooth-muscle actin (SMA) antibodies (Abcam, UK). Then, the sections were washed with PBS followed by a secondary antibody incubation at 37°C for 1 h. The nuclei were stained with 4′,6-diamidino-2-phenylindole (R&D Systems, USA). Finally, the sections were visualized by fluorescence microscopy.

Collection and conservancy of human blood samples {#sec2-4}
-------------------------------------------------

Patients who suffered from chest pain and had undergone coronary angiography were recruited from January 2018 to March 2018 in the Renmin Hospital of Wuhan University. The study protocol was approved by the Medical Ethics Committee of the Renmin Hospital of Wuhan University. The exclusion criteria for this study included patients who were too young or too old (\<20 or \>80 years old) (n=5) and those with severe liver damage, severe renal dysfunction, and a prior history of drug assumption (n=2) ([@ref22]). Meanwhile, all donors in whom other diseases were reported to affect the expression of IL-25 including allergic diseases, autoimmune diseases, and tumor were ruled out.

According to the diagnoses, 37 patients were assigned to the non-CAD group (control group), 44 patients to the stable angina pectoris (SAP) group, 48 patients to the unstable angina pectoris (UAP) group, and 34 patients to the acute myocardial infarction (AMI) group. The CAD patients group included the SAP, UAP, and AMI groups. Vacutainers coated with sodium heparin were used to collect blood samples upon admission. Thirty-four AMI patients underwent reperfusion therapy after blood collection. Serum was isolated after centrifugation for 20 min at 4000 g within 1 h of collection, aliquoted, and stored at −80°C until analysis. In addition, patients with blood sample hemolysis (n=1) in the control group and lipaemia (n=2) in the UAP group were also excluded from this study. All of the donors or their families have provided an informed consent.

Measurement of serum IL-25, IL-6, and TNF-α levels {#sec2-5}
--------------------------------------------------

Serum concentrations of IL-25 (R&D Systems, USA), IL-6, and TNF-α (both from eBioscience, USA) were measured using the enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.

Gensini score {#sec2-6}
-------------

The Gensini score was used to estimate the severity of coronary stenosis according to the results of a coronary angiography as previously reported ([@ref22]). The coronary angiography was conducted by the attending practicing physicians. Then, we recorded the subjects' Gensini scores according to the results of the coronary angiography.

Echocardiography measurement {#sec2-7}
----------------------------

The patients' left ventricular ejection fraction (LVEF) was measured using a VIVID E9 (GE Healthcare, USA) ultrasonography machine as previously reported ([@ref22]). The LVEF values were recorded for all subjects.

Statistical analysis {#sec2-8}
--------------------

The statistical software package SPSS 19.0 was used for data analysis. All data were tested for normality using the Kolmogorov--Smirnov test. Clinical characteristics with normal distribution were presented as mean±standard deviation. Student's t-tests were performed when two normal distribution groups were compared and one-way analysis of variance (ANOVA) was used to test the difference between multiple groups. Data without normal distribution were presented as the median (minimum-maximum) and compared by means of the Mann--Whitney U test. The correlations in continuous variables with normal distribution were evaluated by Pearson correlation analysis. Spearman's correlation analysis was used in continuous variables without normal distribution. Simple linear regression analyzes and subsequent binary logistic regression analyzes were used to identify whether IL-25 was an independent predictor of ACS. A receiver operator characteristic (ROC) curve was used to evaluate the diagnosis value of cytokines in ACS. P\<0.05 was considered statistically significant.

Results {#sec1-3}
=======

Basic clinical characteristics of patients who provided coronary artery tissues {#sec2-9}
-------------------------------------------------------------------------------

From the basic clinical characteristics of the patients who provided coronary artery tissues, several significant differences were found between control and CAD patients, including higher levels of TC and LDL-C, but lower LVEF in CAD patients. However, no difference was observed in other clinical characteristics, including gender, age, smoking, hypertension, BMI, SBP, DBP, Glu, TG, HDL-C, eGFR, CRP, and time. These clinical characteristics of patients are shown in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristics of the patients who provided tissues

  Characteristics    Control               CAD
  ------------------ --------------------- --------------------------------------------------
  Gender (M/F)       3/3                   6/4
  Age (years)        62.0 (46.0-76.0)      62.5 (48.0-73.0)
  Smoking (%)        50                    50
  Hypertension (%)   50                    70
  BMI (kg/m^2^)      20.6 (17.9-23.6)      21.1 (18.8-24.5)
  SBP (mm Hg)        125.5 (118.0-136.0)   118.0 (102.0-137.0)
  DBP (mm Hg)        78.5 (66.0-87.0)      88.5 (68.0-99.0)
  Glu (mmol/L)       5.6 (3.8-6.5)         5.95 (4.9-7.1)
  TG (mmol/L)        1.4 (0.7-1.9)         1.9 (0.9-2.3)
  TC (mmol/L)        3.4 (3.0-4.6)         4.0 (3.4-6.0)[\*](#t1f1){ref-type="table-fn"}
  HDL-C (mmol/L)     1.40 (0.88-1.90)      1.4 (0.9-1.8)
  LDL-C (mmol/L)     2.2 (1.9-3.3)         3.5 (2.0-4.5)[\*](#t1f1){ref-type="table-fn"}
  eGFR (mL/min)      92.0 (80.0-100.0)     87.5 (78.0-104.0)
  CRP (mg/L)         3.0 (0.44-4.5)        3.9 (2.0-4.5)
  LVEF (%)           56.0 (50.0-60.0)      31.0 (24.0-36.0)[\*](#t1f1){ref-type="table-fn"}
  Time (h)           3.4 (2.9-4.0)         3.1 (2.5-4.2)

*P*\<0.05 vs. control. BMI - body mass index; CRP - C-reactive protein; DBP - diastolic blood pressure; eGFR - estimated glomerular filtration rate; Glu - fasting glucose; HDL-C - high-density lipoprotein cholesterol; LDL-C - low-density lipoprotein cholesterol; LVEF - left ventricular ejection fraction; SBP - systolic blood pressure; TC - total cholesterol; TG - total triglycerides; Time - time intervals between the beginning of surgery and collection of tissue sampling; CAD - coronary artery disease; M - male; F - female

Expression of IL-25 in human atherosclerotic plaques {#sec2-10}
----------------------------------------------------

To determine the expression of IL-25 in human atherosclerotic plaques, immunofluorescent staining was performed. We found that IL-25 was highly expressed in coronary arteries with atherosclerotic plaques but lowly expressed in normal arteries ([Fig. 1a](#F1){ref-type="fig"}). Specific antibodies, such as human anti-CD4 antibodies, anti-CD68 antibodies, and anti-α-SMA antibodies, were used to show markers for T-helper cells, macrophages, and smooth muscle cells, respectively. In addition, immunofluorescent double staining displayed that IL-25 was almost not expressed by smooth muscle cells in atherosclerotic arteries but was expressed by macrophages and T lymphocytes, especially the macrophages ([Fig. 1b](#F1){ref-type="fig"}).

![IL-25 expression in human atherosclerotic plaques. (a) IL-25 levels in normal and CAD coronary artery tissues were measured by immunofluorescent staining (200×). (b) Double staining for IL-25 expression, Th cells, macrophages, and smooth muscle cells in atherosclerotic plaques of CAD patients (400×)\
CAD - coronary artery disease](AJC-23-151-g001){#F1}

Basic clinical characteristics of patients who provided blood samples {#sec2-11}
---------------------------------------------------------------------

Serum levels of Glu, LDL-C, and cardiac troponin I (TnI), as well as the percent of smoking and obesity, SBP, DBP, CRP, and the Gensini score were significantly higher in CAD groups when compared to those of the control group. However, there were no significant differences between the control and the CAD groups in terms of other clinical parameters including diabetes and hyperlipidemia, age, HbAlc, TG, TC, HDL-L, eGFR, ALT, LVEF, NT-pro-BNP, and oral hypoglycemia. The basic clinical characteristics of each group are presented in [Table 2](#T2){ref-type="table"}.

###### 

Information of clinical characteristics of patients who provided blood samples

  Characteristics         Control            SAP                                                *P* value   UAP                                                *P* value   AMI                                                      *P* value
  ----------------------- ------------------ -------------------------------------------------- ----------- -------------------------------------------------- ----------- -------------------------------------------------------- -----------
  Elderly (n, %)          16 (44.4%)         24 (54.5%)                                         0.372       20 (43.5%)                                         0.931       16 (47.1%)                                               0.828
  Gender (M/F)            20/16              28/16                                              0.466       31/15                                              0.276       21/13                                                    0.601
  Smoking (n, %)          7 (19.4%)          27 (61.4%)[\*](#t2f1){ref-type="table-fn"}         \<0.001     26 (56.5%)[\*](#t2f1){ref-type="table-fn"}         0.001       20 (58.8%)[\*](#t2f1){ref-type="table-fn"}               0.001
  Obesity (n, %)          16 (44.4%)         38 (86.4%)[\*](#t2f1){ref-type="table-fn"}         \<0.001     36 (78.3%)[\*](#t2f1){ref-type="table-fn"}         0.002       24 (70.6%)[\*](#t2f1){ref-type="table-fn"}               0.028
  Diabetes (n, %)         9 (25.0%)          13 (29.5%)                                         0.653       16 (34.8%)                                         0.343       11 (32.4%)                                               0.499
  Hyperlipidemia (n, %)   14 (38.9%)         12 (27.3%)                                         0.273       15 (32.6%)                                         0.557       16 (47.1%)                                               0.493
  Hypertension (n, %)     25 (69.4%)         38 (86.4%)                                         0.067       33 (71.7%)                                         0.822       24 (70.6%)                                               0.917
  Age (years)             60±16              64±10                                              0.280       63 (43-80)                                         0.691       62±10                                                    0.787
  BMI                     23.7 (21.2-27.6)   25.4 (21.5-29.1)[\*](#t2f1){ref-type="table-fn"}   \<0.001     25.7 (20.9-28.5)[\*](#t2f1){ref-type="table-fn"}   0.003       25.6 (20.9-28.3)[\*](#t2f1){ref-type="table-fn"}         0.007
  Glu (mmol/L)            5.4±1.1            6.8±2.1[\*](#t2f1){ref-type="table-fn"}            \<0.001     6.5 (4.6-11.8)[\*](#t2f1){ref-type="table-fn"}     \<0.001     6.8 (4.3-17.5)[\*](#t2f1){ref-type="table-fn"}           0.001
  HbAlc (%)               5.9 (5.3-6.9)      6.1 (5.3-7.6)                                      0.515       6.2±0.6                                            0.593       6.2±1.0                                                  0.592
  TG (mmol/L)             1.7±0.9            1.6±1.0                                            0.488       1.5 (0.6-3.5)                                      0.866       2.0 (0.7-4.8)                                            0.274
  TC (mmol/L)             4.2 (2.4-7.0)      4.0±1.1                                            0.073       4.4 (2.8-7.7)                                      0.463       4.1 (2.5-6.7)                                            0.477
  HDL-C (mmol/L)          1.1±0.5            1.1 (0.6-1.9)                                      0.957       1.1±0.3                                            0.799       1.0±0.3                                                  0.110
  LDL-C (mmol/L)          2.3±0.7            3.0 (1.5-4.5)[\*](#t2f1){ref-type="table-fn"}      \<0.001     3.1 (1.7-4.6)[\*](#t2f1){ref-type="table-fn"}      \<0.001     3.2 (1.1-4.5)[\*](#t2f1){ref-type="table-fn"}            0.001
  SBP (mm Hg)             155±21             147 (110-210)[\*](#t2f1){ref-type="table-fn"}      0.027       143 (97-180)[\*](#t2f1){ref-type="table-fn"}       0.001       145 (100-221)                                            0.142
  DBP (mm Hg)             86 (69-119)        80 (64-112)[\*](#t2f1){ref-type="table-fn"}        0.027       82 (58-108)[\*](#t2f1){ref-type="table-fn"}        0.016       85 (58-126)                                              0.353
  eGFR (mL/min)           92±6               90 (76-109)                                        0.927       94 (70-110)                                        0.143       91 (75-109)                                              0.995
  ALT (U/L)               36.5 (23.0-49.0)   34.0 (20.0-67.0)                                   0.663       39.2±9.4                                           0.387       35.5 (18.0-74.0)                                         0.787
  AST (U/L)               32.0 (20.0-45.0)   30.0±5.3                                           0.573       30.4±5.8                                           0.959       29.7±7.4                                                 0.444
  CRP (mg/L)              6.4±16.0           28.6±27.9[\*](#t2f1){ref-type="table-fn"}          \<0.001     33.7 (0.2-135.2)[\*](#t2f1){ref-type="table-fn"}   \<0.001     55.8 (3.6-183.0) [\*](#t2f1){ref-type="table-fn"}        \<0.001
  Gensini score           0 (0-0)            18.3±23.7[\*](#t2f1){ref-type="table-fn"}          \<0.001     32.0 (3.0-88.0)[\*](#t2f1){ref-type="table-fn"}    \<0.001     52.5 (2.0-184.0) [\*](#t2f1){ref-type="table-fn"}        \<0.001
  LVEF (%)                54.0 (44.0-67.0)   54.5 (45.0-67.0)                                   0.745       55.0 (45.0-67.0)                                   0.536       54.0 (43.0-67.0)                                         0.568
  NT-pro-BNP (pg/mL)      190±67             186±61                                             0.923       191±62                                             0.918       199±84                                                   0.934
  TnI (10^-3^ ng/L)       13.2 (4.3-34.6)    23.6 (4.2-45.8)[\*](#t2f1){ref-type="table-fn"}    \<0.001     17.7 (8.9-43.2)[\*](#t2f1){ref-type="table-fn"}    0.007       2689.5 (1438.0-5429.0)[\*](#t2f1){ref-type="table-fn"}   \<0.001
  Medications, n (%)                                                                                                                                                                                                                
  Oral hypoglycemics      6 (16.7%)          8 (18.2%)                                          0.860       9 (19.7%)                                          0.738       10 (29.4%)                                               0.208
  Insulin                 1 (2.8%)           5 (11.4%)                                          0.149       5 (10.9%)                                          0.165       3 (8.8%)                                                 0.280
  Aspirin                 17 (47.2%)         24 (54.5%)                                         0.517       25 (54.3%)                                         0.524       19 (55.9%)                                               0.472
  Statin                  8 (22.2%)          16 (36.4%)                                         0.172       19 (41.3%)                                         0.070       19 (55.9%)[\*](#t2f1){ref-type="table-fn"}               0.004
  ACEI/ARB                11 (30.6%)         15 (34.1%)                                         0.739       18 (39.3%)                                         0.423       15 (44.1%)                                               0.244
  Beta-blockers           4 (11.1%)          7 (15.9%)                                          0.538       10 (21.7%)                                         0.207       7 (20.6%)                                                0.280
  CCB                     8 (22.2%)          18 (40.9%)                                         0.078       16 (34.8%)                                         0.218       14 (41.2%)                                               0.090
  Diuretic                2 (5.6%)           3 (6.8%)                                           0.818       3 (6.5%)                                           0.857       1 (2.9%)                                                 0.592

*P*\<0.05 vs. control. ACEI - angiotensin-converting enzyme inhibitor; ALT - alanine aminotransferase; ARB - angiotensin receptor blocker; AST - aspartate transaminase;

AMI - acute myocardial infarction; BMI - body mass index; CCB - calcium channel blocker; CRP - C-reactive protein; cTnI - cardiac troponin I; DBP - diastolic blood pressure;

eGFR - estimated glomerular filtration rate; Glu - fasting glucose; HbA1c - hemoglobin A1c; HDL-C - high-density lipoprotein cholesterol; LDL-C - low-density lipoprotein cholesterol; LVEF - left ventricular ejection fraction; NT-pro-BNP - N-terminal pro-brain-type natriuretic peptide; SBP - systolic blood pressure; SAP - stable angina pectoris;

UAP - unstable angina pectoris; TG - total triglycerides; TC - total cholesterol

Serum IL-25, IL-6, and TNF-α levels in the four groups {#sec2-12}
------------------------------------------------------

According to the results of the ELISA, IL-25 levels were significantly higher in the CAD patients compared to those in the control group ([Table 3](#T3){ref-type="table"}) and gradually increased in the SAP, UAP, and AMI groups (150.7 pg/mL vs. 379.8 pg/mL vs. 484.7 ng/mL vs. 634.3 ng/mL, p\<0.05) ([Fig. 2a](#F2){ref-type="fig"}). Homoplastic changes were found in IL-6 and TNF-α levels ([Fig. 2b](#F2){ref-type="fig"} and [2c](#F2){ref-type="fig"}); however, not all of the differences noted were statistically significant. The serum levels of the various cytokines in the four groups of patients are listed in [Table 3](#T3){ref-type="table"}.

###### 

Serum IL-25, IL-6, and TNF-α levels in each group

                  Control              SAP                                                  *P* value   UAP                                                   *P* value   AMI                                                    *P* value
  --------------- -------------------- ---------------------------------------------------- ----------- ----------------------------------------------------- ----------- ------------------------------------------------------ -----------
  IL-25 (pg/mL)   150.7 (33.2-292.4)   379.8 (57.3-699.3)[\*](#t3f1){ref-type="table-fn"}   \<0.001     484.7 (180.9-841.0)[\*](#t3f1){ref-type="table-fn"}   \<0.001     634.3 (135.7-1058.0)[\*](#t3f1){ref-type="table-fn"}   \<0.001
  IL-6 (pg/mL)    21.4±11.8            34.4±28.3                                            0.106       57.8 (1.5-183.9)[\*](#t3f1){ref-type="table-fn"}      \<0.001     107.5 (16.4-196.4)[\*](#t3f1){ref-type="table-fn"}     \<0.001
  TNF-α (pg/mL)   30.4 (0.6-90.0)      80.0±51.9[\*](#t3f1){ref-type="table-fn"}            \<0.001     127.3 (20.4-248.1)[\*](#t3f1){ref-type="table-fn"}    \<0.001     139.1 (39.5-301.5)[\*](#t3f1){ref-type="table-fn"}     \<0.001

*P*\<0.05 vs. control. Values are median, unless otherwise stated. Values in parentheses are minimum and maximum. Mann--Whitney U test was used to compare the concentrations of IL-25, IL-6, and TNF-α in CAD serum. SAP - stable angina pectoris; UAP - unstable angina pectoris; AMI - acute myocardial infarction; TNF-α - tumor necrosis factor-α

![Serum IL-25, IL-6, and TNF-α levels in the four groups. (a) Serum IL-25 levels in patients with SAP, UAP, AMI, and control groups were measured. (b) Serum IL-6 levels were measured in the four groups. (c) Serum TNF-α levels were measured in each group](AJC-23-151-g002){#F2}

The correlation between serum cytokine levels and the Gensini score {#sec2-13}
-------------------------------------------------------------------

Pearson correlation analysis or Spearman's correlation analysis were performed in 124 CAD patients to evaluate the relationship among IL-25, IL-6, and TNF-α and the Gensini score. The results showed that serum levels of IL-25 were markedly positively correlated with IL-6 (r=0.304, p\<0.001) and TNF-α (r=0.403, p\<0.001). The concentrations of IL-6 were also identified to be positively correlated with TNF-α (r=0.201, p=0.026). Additionally, the concentrations of serum IL-25 (r=0.495, p\<0.001), IL-6 (r=0.440, p\<0.001), and TNF-α (r=0.507, p\<0.001) were positively correlated with the Gensini score ([Fig. 3a](#F3){ref-type="fig"}--[3c](#F3){ref-type="fig"}).

![Spearman's correlation of circulating cytokines and Gensini score. Correlation among (a) IL-25 levels, (b) IL-6 levels, (c) TNF-α levels, and Gensini score](AJC-23-151-g003){#F3}

The association between serum IL-25 and ACS {#sec2-14}
-------------------------------------------

Simple linear regression analysis and binary logistic regression analysis were performed to confirm whether IL-25 is a possible predictor for ACS. The results of the simple linear regression analysis suggested that IL-25, IL-6, TNF-α, cTnI, CRP, Glu, LDL, and SBP levels showed a potential (p\<0.05) correlation with the onset of ACS whereas smoking, DBP, BMI, HbAlc, TC, age, and gender showed no obvious trends (p\>0.05) with the onset of ACS. Furthermore, IL-25, IL-6, TNF-α, cTnI, CRP, Glu, LDL, and SBP levels were used to perform binary logistic regression analysis. The further results showed that serum levels of IL-25 (OR 1.006, 95% CI 1.002 to 1.011; p=0.004), IL-6 (OR 1.036, 95% CI 1.017 to 1.055; p\<0.001), and Glu (OR 1.471, 95% CI 1.040 to 2.081; p=0.029) seemed to be independent predictors for ACS ([Table 4](#T4){ref-type="table"}). In this study, part of variables including TNF-α, cTnI, CRP, LDL, and SBP levels were not the independent predictors for the occurrence of ACS.

###### 

Association between cytokines, clinical characteristics, and the presence of acute coronary syndrome assessed by simple linear regression analysis and further multiple linear regression analysis

  Variables   Simple linear   *P* value          Binary logistic   *P* value                     
  ----------- --------------- ------------------ ----------------- ----------- ----------------- ---------
  IL-25       0.644           0.524 to 0.764     \<0.001           1.006       1.002 to 1.011    0.004
  IL-6        0.591           0.465 to 0.718     \<0.001           1.036       1.017 to 1.055    \<0.001
  TNF-α       0.548           0.417 to 0.680     \<0.001           1.011       1.000. to 1.021   0.052
  cTnI        0.485           0.348 to 0.623     \<0.001           1.002       0.997 to 1.007    0.470
  CRP         0.409           0.265 to 0.552     \<0.001           1.016       0.998 to 1.035    0.079
  Glu         0.239           0.086 to 0.391     0.002             1.471       1.040 to 2.081    0.029
  LDL-C       0.225           0.072 to 0.378     0.004             1.359       0.574 to 3.218    0.486
  SBP         -0.156          -0.311 to -0.001   0.049             0.981       0.954 to 1.009    0.176
  DBP         -0.081          -0.237 to 0.076    0.310                                           
  TC          0.121           -0.035 to 0.277    0.128                                           
  Age         0.017           -0.014 to 0.174    0.829                                           
  Gender      0.052           -0.105 to 0.209    0.517                                           
  BMI         0.092           -0.064 to 0.249    0.246                                           
  Smoking     0.150           -0.005 to 0.305    0.058                                           
  HbA1c       0.077           -0.080 to 0.233    0.335                                           

BMI - body mass index; CRP - C-reactive protein; cTnI - cardiac troponin I; DBP - diastolic blood pressure; Glu - fasting glucose; HbA1c - hemoglobin A1c; LDL-C - low-density lipoprotein cholesterol; SBP - systolic blood pressure; TC - total cholesterol; TNF-α - tumor necrosis factor-α

The diagnostic value of cytokines and cTnI in ACS {#sec2-15}
-------------------------------------------------

We further applied ROC analysis on diagnostic values of serum cTnI, IL-25, IL-6, and TNF-α concentrations in ACS. As shown in [Figure 4a](#F4){ref-type="fig"} and [4b](#F4){ref-type="fig"}, each of these cytokines and cTnI seem to have particular diagnostic value for ACS, whereas the combination of three cytokines presented a bit more preferable diagnostic value than three cytokines individually did in ACS.

![Diagnostic value of cytokines and cTnI in ACS. (a) ROC curve of IL-25, IL-6, TNF-α, and combining the three cytokines for ACS. (b) ROC curve of IL-25, IL-6, and TNF-α, combining the three cytokines and cTnI for ACS](AJC-23-151-g004){#F4}

Discussion {#sec1-4}
==========

In the present study, we found for the first time that IL-25 was increased in human atherosclerotic arteries and that T lymphocytes and macrophages, especially the macrophages, rather than smooth muscle cells, were the source of IL-25 in atherosclerotic plaques. We also found that IL-25 levels were increased in the serum of CAD patients and positively correlated with the severity of coronary stenosis. Binary logistic regression analysis suggested that IL-25 might independently correlate with the onset of ACS.

Previous studies had demonstrated that IL-25 was associated with the progression of various diseases of the immune system, such as asthma ([@ref23]), rheumatoid arthritis ([@ref24]), multiple sclerosis ([@ref25]) and inflammatory bowel disease ([@ref26]). However, IL-25 expression in various diseases involving other systems is controversial. Growing evidence has shown that IL-25 is upregulated in serum of patients with allergic diseases such as respiratory diseases exacerbated by aspirin ([@ref27]) but without significant changes in patients with severe asthma ([@ref28]) or uncontrolled asthma ([@ref29]). In addition, Aalberse et al. ([@ref30]) showed that IL-25 was also highly enhanced in children's plasma response to peanuts. In autoimmune diseases, IL-25 was observed to be elevated in the plasma of rheumatoid arthritis patients and serum of Churg-Strauss syndrome patients compared to healthy individuals ([@ref31], [@ref32]). In our study, the results showed that serum concentrations and atherosclerotic plaques expression of IL-25 in CAD patients were significantly increased and that IL-25 was also positively correlated with the Gensini score, further confirming that IL-25 levels may be closely related with the severity of coronary stenosis. These results suggested that IL-25 might play an important role in the progression of atherosclerosis.

After it was first found to be expressed by Th2-polarized CD4+ T cells, IL-25 has been identified to be extensively produced and to locally or generally participate in inflammatory, infectious, or autoimmune diseases ([@ref33]-[@ref35]). IL-25 has been identified to be produced by several different cells, such as bone marrow-derived mast cells ([@ref36]), alveolar macrophages ([@ref37]), eosinophils, basophils ([@ref38]), epithelial, ([@ref15]) and endothelial cells ([@ref39]). Our results of immunofluorescence double staining were consistent with the above conclusions, and for the first time, we suggest that macrophages and T lymphocyte are important sources of IL-25 in human atherosclerotic plaques. This suggestion is a significant addition to the sources of IL-25 and indicates that IL-25 may influence the development of atherosclerosis via regulation of the inflammatory response.

Atherosclerosis is well known to be an underlying pathophysiological mechanism of CAD and various inflammatory cells and factors have been identified to play important roles in the development of atherosclerosis ([@ref40]). Clinical, experimental, and animal studies have supported the hypothesis that inflammatory cells are recruited to the intima during the beginning of atherosclerosis and monocytes further differentiate into tissue macrophages after translocation to the arteries and subsequently become foam cells. In response to the development of an atheroma, one type of macrophages named M1 macrophages have the function of secreting the proinflammatory cytokines such as IL-1β and TNF-α, which are involved in the stimulation of IL-6 production ([@ref41]). Kampits et al. ([@ref42]) reported that CAD patients who experienced major events had higher concentrations of TNF-α and IL-6. Min et al. ([@ref43]) found that serum levels of TNF-α and IL-6 were significantly more elevated in ACS patients than those in controls and that these levels were associated with high Gensini scores. In our present study, we found that the concentrations of serum TNF-α and IL-6 are not only increased in CAD patients but also associated with IL-25 levels and Gensini scores, which reflect the severity of coronary stenosis. Our results are consistent with previous findings and further suggested the predictive role of TNF-α and IL-6 in CAD as shown in the Spearman correlation analysis and logistic regression analysis. Therefore, we surmised that IL-25 could affect levels of TNF-α and IL-6 in CAD patients.

As important members of inflammatory cytokines, IL-6, and TNF-α have been identified to be synthesized by macrophages, B cells, CD4 effector T-helper cells, and some other immune cells ([@ref44]). As a Th2 cytokine, IL-25 has been reported to regulate several inflammatory and immune cells in the progression of several diseases. For instance, Kleinschek et al. ([@ref45]) suggested that experimental autoimmune encephalomyelitis IL-25 knockout mice presented increased levels of IL-23 in the periphery and enhanced T cells in the central nervous system, which produced IL-17, IFN-γ, and TNF. IL-25 also enhanced the functions of Th2 memory cells through the sustained expression of GATA-3, c-MAF, and JunB independent of IL-4 ([@ref38]). In contact hypersensitivity induced by fluorescein isothiocyanate, IL-25 secreted by mast cells and nonimmune cells can stimulate dermal dendritic cells to produce IL-1β and contributes to the activation of Th17 instead of Th2 cells ([@ref46]). Furthermore, with exogenous IL-25 treatment of apoE/Rag-1 deficient mice, splenic innate lymphoid type 2 cells were extensively enhanced and plasma IL-5 was also increased. In addition, apoE-deficient mice presented reduced aortic atherosclerosis after injection of recombinant IL-25, which suggests that IL-25 may have a protective role in atherosclerosis ([@ref21]). IL-25 deficient mice were also used and showed an aggravation of the aortic atherosclerotic plaques with elevated Th1/Th17 proinflammatory response, suggesting a role for IL-25 in the maintenance of the T cells in patients suffering from hyperlipidemias ([@ref47]). Our studies first found that high serum IL-25 levels were associated with an increased risk of suffering ACS. Data in ROC analysis suggested that IL-25 might have the function of reflecting the stability of plaque. The small sample size of our study might contribute to these results, although further large amount of subjects will be more convincing. These results indicated that inflammatory cytokine IL-25 would be tightly related to atherosclerosis progress, especially unstable plaque, and shows potential to be a biomarker for ACS patients.

Study limitations {#sec2-16}
-----------------

However, there are some limitations in the present study. For instance, oxidative stress, which also plays critical roles in the development of atherosclerosis, might be another mechanism for IL-25 involving in ACS. Therefore, further investigations should concentrate on the relationship between IL-25 and oxidative stress in atherosclerosis. Another limitation of the study is that the number of the patients was too small and more subjects should be included to reduce any margins of error.

Conclusion {#sec1-5}
==========

The results of our study identified that IL-25 is highly expressed in atherosclerotic arteries of CAD patients and is mainly produced by macrophages and T lymphocyte cells. Additionally, IL-25 levels in serum were first significantly increased in CAD patients especially in AMI patients and positively correlated with the severity of coronary atherosclerosis. Further analysis identified that high serum IL-25 levels were associated with an increased risk of suffering plaque instability and high predictive value of IL-25 in ACS.
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